MemoBoost

Drug Treatment to Inhibit Dementia

Health Tech & Life Sciences
Non Active, May 2024 ceased to operate
Seed Haifa, Israel Founded 2016
Last updated 2026-06-18
Total raised
Last: 2016-06
Stage
Seed
Founded
2016
Headcount
6
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

MemoBoost is developing a pioneering drug treatment designed to inhibit the onset of dementia. The companys technology is based on research into the scientific foundations of learning and memory in the brain. MemoBoost is headed by Prof. Edi Barkai of the University of Haifas Sagol Department of Neurobiology and the head of the Laboratory for Neurobiology of Learning and Memory. Prof. Barkai is on the path to developing a cognitive/learning-enhancing drug that may counter the cognitive deficits suffered by dementia patients. Prof. Barkais research has identified a specific receptor in the brain, in the mGluR family, which inhibits learning when its excitability is blocked and improves learning when its excitability is consistently enhanced. Using a research compound that activates this receptor, Prof. Barkais group has successfully shown that learning is significantly enhanced in a validated animal model of learning. The compound is currently being modified and tested in order to develop a drug that will serve as a potent cognitive enhancer to tackle the onset of dementia and other cognitive deficits.

Funding history · 1 round · — total

2016-06

Q&A

What is the current status of MemoBoost?
MemoBoost is currently inactive and ceased to operate in May 2024.
What is MemoBoost's primary focus?
MemoBoost is developing a drug treatment to inhibit the onset of dementia, based on research into learning and memory in the brain.
When was MemoBoost founded?
MemoBoost was founded in March 2016.
Where is MemoBoost headquartered?
MemoBoost is headquartered in Haifa, North District, Israel.
Who is leading the research at MemoBoost?
Prof. Edi Barkai of the University of Haifa's Sagol Department of Neurobiology is heading MemoBoost's research.
What type of drug is MemoBoost developing?
MemoBoost is developing a cognitive/learning-enhancing drug that targets a specific mGluR family receptor in the brain to counter cognitive deficits in dementia patients.
Which investor participated in MemoBoost's funding round?
Carmel Innovation Fund participated in MemoBoost's funding round in June 2016.

Team · 1

Founder · Researcher

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProviders
Business model
B2B

Tags

pharmaceuticalsbrain-disorderpatent-pendingalzheimers-diseasepreventionpharma-companiestreatmentsdrug-discovery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2016-3
Employees (exact)6
Status reasonNon Active, May 2024 ceased to operate